RECIST Criteria Flashcards
Question 1: Topic - RECIST Criteria for Target Lesions (Complete Response)
A 58-year-old male with bladder cancer has been on targeted therapy. A recent imaging study reveals the disappearance of all target lesions and the lymph nodes show a reduction in short axis to <10 mm. According to RECIST criteria, how would you classify the response?
A. Partial Response (PR)
B. Stable Disease (SD)
C. Complete Response (CR)
D. Progressive Disease (PD)
Correct Answer: C. Complete Response (CR)
Explanation: According to RECIST criteria, a complete response in the evaluation of target lesions is characterized by the disappearance of all target lesions and any pathological lymph nodes must have a reduction in the short axis to <10 mm (Paragraph 1, Table 6.1).
Memory Tool: Think “CR = Cancer Removed” to remember the criteria for Complete Response.
Rationale: Understanding the RECIST criteria is essential for interpreting treatment outcomes and for designing treatment plans.
Reference Citation: Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228–247, 2009.
Question 2: Topic - RECIST Criteria for Target Lesions (Progressive Disease)
A 47-year-old woman with renal cell carcinoma has been on immunotherapy. Her latest scans show a 25% increase in the sum of diameters of target lesions from the smallest sum recorded in the study. The sum also shows an absolute increase of 7 mm. No new lesions were detected. How would you categorize her response according to RECIST?
A. Partial Response (PR)
B. Stable Disease (SD)
C. Complete Response (CR)
D. Progressive Disease (PD)
Correct Answer: D. Progressive Disease (PD)
Explanation: The RECIST criteria specify that Progressive Disease (PD) in target lesions is defined as at least a 20% increase in the sum of diameters, taking as a reference the smallest sum on study. There should also be an absolute increase of at least 5 mm (Paragraph 1, Table 6.1).
Memory Tool: PD = “Progressively Deteriorating” to remember the criteria for Progressive Disease.
Rationale: Recognizing progression of disease is crucial for adjusting the therapeutic strategy.
Reference Citation: Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228–247, 2009.
Question 3: Topic - RECIST Criteria for Nontarget Lesions (Complete Response)
In a 36-year-old patient with prostate cancer, all non-target lesions have disappeared, and the tumor marker levels have normalized. However, one lymph node remains at 12 mm in size. What would this patient’s nontarget lesion response be?
A. Complete Response (CR)
B. Non-CR/Non-PD
C. Progressive Disease (PD)
D. Stable Disease (SD)
Correct Answer: B. Non-CR/Non-PD
Explanation: According to RECIST criteria, a Complete Response (CR) for nontarget lesions would require all lymph nodes to be <10 mm in size along the short axis. Since one lymph node remains at 12 mm, the patient cannot be classified as having a Complete Response (Paragraph 2, Table 6.1).
Memory Tool: If not completely right, it’s Non-CR/Non-PD.
Rationale: It’s crucial to distinguish between complete and non-complete responses in nontarget lesions for accurate evaluation.
Reference Citation: Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228–247, 2009.
Question 4: Topic - RECIST Criteria for Target Lesions (Partial Response)
A 52-year-old male with testicular cancer undergoes chemotherapy. Post-treatment, imaging shows a 35% decrease in the sum of the diameters of target lesions from the baseline sum. How should the patient’s response be classified according to RECIST criteria?
A. Partial Response (PR)
B. Stable Disease (SD)
C. Complete Response (CR)
D. Progressive Disease (PD)
Correct Answer: A. Partial Response (PR)
Explanation: The RECIST criteria state that a Partial Response (PR) in target lesions is marked by at least a 30% decrease in the sum of diameters, taking as reference the baseline sum diameters (Paragraph 1, Table 6.1).
Memory Tool: PR = “Pretty Reduced” to remember the criteria for Partial Response.
Rationale: Accurate classification of Partial Response helps to determine if the therapy is effective and informs the next steps in the treatment plan.
Reference Citation: Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228–247, 2009.
Question 5: Topic - RECIST Criteria for Target Lesions (Stable Disease)
A 60-year-old female with ureteral cancer is under targeted therapy. After several months, imaging reveals neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD when compared to the smallest sum diameters recorded while on study. What is the RECIST classification of her response?
A. Stable Disease (SD)
B. Complete Response (CR)
C. Partial Response (PR)
D. Progressive Disease (PD)
Question 5: Topic - RECIST Criteria for Target Lesions (Stable Disease)
A 60-year-old female with ureteral cancer is under targeted therapy. After several months, imaging reveals neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD when compared to the smallest sum diameters recorded while on study. What is the RECIST classification of her response?
A. Stable Disease (SD)
B. Complete Response (CR)
C. Partial Response (PR)
D. Progressive Disease (PD)
Question 6: Topic - RECIST Criteria for Nontarget Lesions (Progressive Disease)
A 44-year-old patient with kidney cancer has multiple non-target lesions. Imaging reveals unequivocal progression of existing non-target lesions. There are no new lesions. According to RECIST criteria, what is the classification for nontarget lesions?
A. Complete Response (CR)
B. Non-CR/Non-PD
C. Progressive Disease (PD)
D. Stable Disease (SD)
Correct Answer: C. Progressive Disease (PD)
Explanation: RECIST criteria specify that Progressive Disease (PD) for nontarget lesions is identified by unequivocal progression of existing non-target lesions (Paragraph 2, Table 6.1).
Memory Tool: PD = “Problem Detected” to remember Progressive Disease in nontarget lesions.
Rationale: Monitoring the progression in nontarget lesions is crucial for the overall management of the disease.
Reference Citation: Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228–247, 2009.
